High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates
1
Issued Date
2022-01-01
Resource Type
eISSN
22221751
Scopus ID
2-s2.0-85135164206
Pubmed ID
35792049
Journal Title
Emerging Microbes and Infections
Volume
11
Issue
1
Start Page
1857
End Page
1866
Rights Holder(s)
SCOPUS
Bibliographic Citation
Emerging Microbes and Infections Vol.11 No.1 (2022) , 1857-1866
Suggested Citation
Trisakul K., Nonghanphithak D., Chaiyachat P., Kaewprasert O., Sakmongkoljit K., Reechaipichitkul W., Chaiprasert A., Blair D., Clark T.G., Faksri K. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Emerging Microbes and Infections Vol.11 No.1 (2022) , 1857-1866. 1866. doi:10.1080/22221751.2022.2099304 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87417
Title
High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates
Other Contributor(s)
Abstract
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) make TB difficult to control. Global susceptibility data for six newly recommended anti-TB drugs against M/XDR-TB are still limited. Using publicly available whole-genome sequences, we determined the proportion of 513 phenotypically XDR-TB isolates that carried mutations associated with resistance against these drugs (bedaquiline, clofazimine, linezolid, delamanid, pretomanid and cycloserine). Mutations of Rv0678 and Rv1979c were detected in 69/513 isolates (13.5%) for bedaquiline resistance and 79/513 isolates (15.4%) for clofazimine resistance with additional mmpL5 mutations. Mutations conferring resistance to delamanid were detected in fbiB and ddn genes for 11/513 isolates (2.1%). For pretomanid, a mutation was detected in the ddn gene for 3/513 isolates (0.6%). Nineteen mutations of pykA, cycA, ald, and alr genes, conferring resistance to cycloserine, were found in 153/513 isolates (29.8%). No known mutations associated with linezolid resistance were detected. Cluster analysis showed that 408/513 isolates fell within 99 clusters and that 354 of these isolates were possible primary drug-resistant TB (292 XDR-TB, 57 pre-XDR-TB and 5 MDR-TB). Clonal transmission of primary XDR isolates might contribute significantly to the high prevalence of DR-TB globally.